470 related articles for article (PubMed ID: 34149612)
1. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
[TBL] [Abstract][Full Text] [Related]
3. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
5. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
Janssen JAMJL; Smith TJ
Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
7. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
Smith TJ
Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
[TBL] [Abstract][Full Text] [Related]
8. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
Smith TJ; Janssen JAMJL
Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
[TBL] [Abstract][Full Text] [Related]
10. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
11. TSHR as a therapeutic target in Graves' disease.
Smith TJ
Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991
[TBL] [Abstract][Full Text] [Related]
12. Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():129-148. PubMed ID: 30044728
[TBL] [Abstract][Full Text] [Related]
13. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
Ding Y; Yang S; Gao H
Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
[TBL] [Abstract][Full Text] [Related]
14. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
Girnita L; Smith TJ; Janssen JAMJL
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
[TBL] [Abstract][Full Text] [Related]
15. The effect of acromegaly on thyroid disease.
Mo C; Zhong L
Endocr J; 2023 Nov; 70(11):1051-1060. PubMed ID: 37880078
[TBL] [Abstract][Full Text] [Related]
16. IGF1 receptor and thyroid-associated ophthalmopathy.
Mohyi M; Smith TJ
J Mol Endocrinol; 2018 Jul; 61(1):T29-T43. PubMed ID: 29273685
[TBL] [Abstract][Full Text] [Related]
17. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
18. Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.
Smith TJ; Janssen JA
Front Endocrinol (Lausanne); 2016; 7():167. PubMed ID: 28096798
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
Slentz DH; Nelson CC; Smith TJ
Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
[TBL] [Abstract][Full Text] [Related]
20. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
Chen H; Mester T; Raychaudhuri N; Kauh CY; Gupta S; Smith TJ; Douglas RS
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]